erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
it causes stroke and dementia as well as mood disturbance. svd increases with age but is accelerated by hypertension and diabetes...